Corestem Shares Protocol for Long-term NeuroNata-R Trial

Corestem Shares Protocol for Long-term NeuroNata-R Trial

Corestem is still enrolling participants in its Phase 3 clinical trial of NeuroNata-R (lenzumestrocel), a stem cell therapy that is conditionally approved to treat amyotrophic lateral sclerosis (ALS) in South Korea. The trial, ALSummit (NCT04745299), is evaluating the safety of repeat NeuroNata-R injections and how well…

FDA Shares Plan for ALS, Other Neurodegenerative Diseases

The U.S. Food and Drug Administration (FDA) has published on its website a five-year action plan meant to help advance the development of — and access to — treatments that may make life better and longer for people with amyotrophic lateral sclerosis (ALS) or other rare neurodegenerative diseases. The…

PrimeC Therapy Added to Standard Care Gets ALS Biomarkers Down

NeuroSense Therapeutics’ combination therapy PrimeC led to a significant decline in certain biomarkers of amyotrophic lateral sclerosis (ALS) when used as an add-on to standard of care treatment, a study found. Standard treatment alone, meanwhile, appeared to have no impact on these disease-related biomarkers. The preliminary results come from…

In Memoriam: Rick Jobus, Feb. 6, 1958-June 19, 2022

Courtesy of Rick Jobus It is with deep sadness that we inform the ALS News Today community of the passing of our friend and treasured columnist, Rick Jobus, on June 19, 2022. Rick published the first installment of his column, “Notes From the ALS Front,”…